NEW YORK, July 22, 2015 /PRNewswire/ --
ACI Association has initiated research coverage on Amyris, Inc.
(NASDAQ: AMRS). Select highlights from the internally released
reports are being made available to the general public (included
below), with access to the entirety of the research available to
new members.
Today, membership is open to readers on a complementary basis at
the following URL: http://www.aciassociation.com/?c=AMRS
Highlights from our AMRS Report include:
- First Agreement in Food Sector - On
July 16, 2015, Amyris, Inc. announced
that it has entered into a multi-year, multi-million-dollar
collaboration agreement with a global food ingredients supplier.
This partnership represents its first collaboration in the growing
food ingredients sector. Following the announcement, the Company's
shares soared 11.73% to close the session at $2.00.
- Details of the Agreement - Under the agreement, the
partner, whose name was not disclosed by the Company, will provide
funding for the development program, which will be executed by
Amyris. Additionally, the agreement includes a long-term value
share provision in regard to future end-market product sales by the
partner.
- Management Statements - Commenting on the
partnership, John Melo, President
and CEO of Amyris, stated, "We're excited with the continued
momentum in executing our plan with growing our collaboration
partnerships. This collaboration adds to our current portfolio of
collaboration partners and our growing portfolio of over 20
products under agreement with more than 10 partners." Melo added,
"We are on track to introduce three new commercial products this
year for our partners as a result of our earlier collaborations.
Collaborations continue to fund our direct R&D costs and
provide strong product revenue growth."
- Other Recent Agreements - On June 25, 2015, the Company had announced an
exclusive re-seller agreement for its Neossance® cosmetic
ingredients with Dinaco Importação Comércio S.A. - a Brazilian
company specializing in cosmetic product distribution for the
Brazilian market. As part of the agreement, Dinaco, which
distributes products and ingredients for many of the world's most
important cosmetics and other manufacturers, would purchase and
exclusively re-sell Amyris's Neossance® Squalane and Neossance®
Hemisqualane products throughout Brazil. Previously, on June 9, 2015, the Company announced the signing
of a Letter of Intent (LOI) to establish an agreement for Amyris to
supply a key starting material for an active pharmaceutical
ingredient to Mumbai, India-based
Ipca Laboratories Ltd.
To find out how this influences our rating on Amyris, Inc., read
the full report in its entirely here:
http://www.aciassociation.com/?c=AMRS
About ACI Association:
Active Charter Investors Association ("ACI Association")
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
equities listed on NYSE and NASDAQ and micro-cap stocks. ACI
Association has two distinct and independent departments. One
department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ACI Association has not been compensated; directly or
indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ACI Association, the Author, the Reviewer and the CFA®
(collectively referred to as the "Publishers") are not responsible
for any error which may be occasioned at the time of printing of
this document or any error, mistake or shortcoming. No liability is
accepted by the Publishers whatsoever for any direct, indirect or
consequential loss arising from the use of this document. The
Publishers expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, the Publishers do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The
included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ACI Association nor any party affiliated
with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our
report(s), read our disclosures, or for more information, visit
http://www.aciassociation.com/.
RESTRICTIONS
ACI Association is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) aciassociation.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.aciassociation.com